Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast - 2032

Acute Respiratory Distress Syndrome (ARDS) - Epidemiology Forecast - 2032

DelveInsight's ‘Acute Respiratory Distress Syndrome- Epidemiology Forecast–2032' report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome, historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Acute Respiratory Distress Syndrome Disease Understanding

Acute respiratory distress syndrome (ARDS) is a severe lung condition that causes low blood oxygen. People who develop ARDS are usually ill due to another disease or a major injury. In ARDS, fluid builds up inside the tiny air sacs of the lungs, and surfactant breaks down.

ARDS may develop over a few days, or it can get worse very quickly. Usually, the first symptom of ARDS is shortness of breath. Besides, other signs and symptoms of ARDS are low blood oxygen, rapid breathing, and clicking, bubbling, or rattling sounds in the lungs when breathing.

ARDS is generally characterized by three stages such as exudative stage, fibroproliferative (or proliferative) stage, resolution, and recovery stage. The exudative stage is the accumulation of protein, excessive fluid and inflammatory cells in the alveoli occur in the exudative stage. This phase usually is seen within the first 2 to 4 days after the onset of lung injury. Fibroproliferative (or proliferative) stage is the proliferation of connective tissue and other structural elements in the lungs in response to the initial lung injury. The chances of a patient having pneumonia sepsis and rupture of the lungs are very high in this stage. Resolution and Recovery are in this stage, the lung reorganizes and recovers. During this stage, lung function may continue to improve in patients. The fourth phase of ARDS is also seen according to some experts in which when some patients due to acute illness have continued health problems while some may experience anxiety, depression, and flashback memories of their critical illness, which are very similar to post-traumatic stress disorder. This stage is still an area under research.

Acute Respiratory Distress Syndrome Diagnosis

Early recognition of ARDS is important for the timely initiation of lung-protective ventilation strategies. Even after attempts to improve the definition of the disease, ARDS remains under-recognized by clinicians. Oftentimes, when a diagnosis is made, it has been after a significant delay. The rate of under-diagnosis is reported to be as high as 40%, with higher rates of diagnosis with increasing disease severity. ARDS is a syndrome with several different clinical criteria that must be fulfilled; however, none of these data points is particularly precise. The current clinical criteria have low specificity, for example, 63% for the Berlin definition to identify DAD at autopsy. At present, no biomarker is present to aid in the diagnosis, and this is now an area of much active research.

Chest X-rays for the diagnosis of ARDS have relatively low sensitivity and specificity of approximately 70% when compared to CT scans. CXR performs better when the infiltrates are diffuse or patchy as opposed to focal. The use of CT scans and other imaging techniques in the diagnosis and management of ARDS has become increasingly important. Lung ultrasound is another modality that can be used as a bedside tool to facilitate the diagnosis of ARDS.

Continued in the report…..

Acute Respiratory Distress Syndrome Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident cases of Acute Respiratory Distress Syndrome, severity-specific cases of Acute Respiratory Distress Syndrome, and incident cases of Acute Respiratory Distress Syndrome by risk factors scenario of Acute Respiratory Distress Syndrome in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Acute Respiratory Distress Syndrome Detailed Epidemiology Segmentation

Total incident cases of Acute Respiratory Distress Syndrome in the 7MM were found to be 1,187,682 cases in 2021. These cases are expected to change by 2032 at a CAGR of 1.5% during the study period (2019–2032).

Among 7MM, the United States has the highest number of incident cases of Acute Respiratory Distress Syndrome with 634,515 cases in 2021.

Assessments as per DelveInsight's analysts show that in terms of severity-specific incidence, a similar trend is observed in all countries, with a majority of the cases pointing to moderate ARDS, except France, where severe cases of ARDS accounted for a maximum patient population.

In the United States, there were a total of 190,355, 295,684, and 148,477 severity-specific cases of mild, moderate, and severe Acute Respiratory Distress Syndrome respectively, in 2021. As per DelveInsight's analysts, the severity-specific cases of Acute Respiratory Distress Syndrome will increase by 2032.

In EU-5, Germany has the highest number of incident cases of Acute Respiratory Distress Syndrome with 216,462 cases in 2021, followed by France with 115,168 cases and Italy with 72,878 cases. While the United Kingdom has the least number of cases with 36,976 in 2021.

In 2021, Japan had 73,039 incident cases of Acute Respiratory Distress Syndrome.

Scope of the Report

The report covers the descriptive overview of Acute Respiratory Distress Syndrome, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.

The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The report assesses the disease risk and burden of Acute Respiratory Distress Syndrome.

The report helps to recognize the growth opportunities in the 7MM concerning the patient population.

The report provides the segmentation of the disease epidemiology for 7MM, a total number of incident cases of Acute Respiratory Distress Syndrome, severity-specific cases of Acute Respiratory Distress Syndrome, and incident cases of Acute Respiratory Distress Syndrome by risk factors.

Report Highlights

11-Year Forecast of Acute Respiratory Distress Syndrome

The 7MM Coverage

Total incident cases of Acute Respiratory Distress Syndrome

Severity-specific Cases of Acute Respiratory Distress Syndrome

Incident cases of Acute Respiratory Distress Syndrome by risk factors

Key Questions Answered

What are the disease risk and burdens of Acute Respiratory Distress Syndrome?

What is the historical Acute Respiratory Distress Syndrome patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?

What would be the forecasted patient pool of Acute Respiratory Distress Syndrome at the 7MM level?

What will be the growth opportunities across the 7MM concerning the patient population with Acute Respiratory Distress Syndrome?

Out of the above-mentioned countries, which country would have the highest incident population of Acute Respiratory Distress Syndrome during the forecast period (2022–2032)?

At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

Reasons to buy

The Acute Respiratory Distress Syndrome report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the 7MM Acute Respiratory Distress Syndrome epidemiology forecast.

The Acute Respiratory Distress Syndrome epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.

The Acute Respiratory Distress Syndrome epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

Patient Segmentation

Disease Risk and Burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population

Geographies Covered

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2019–2032